Shots: BMS has exercised its option to an exclusive WW license to a cell therapy based on Obsidian’s cytoDRiVE technology for the controlled expression of the immunomodulatory factor CD40L In […]readmore
Tags : License
Shots: I-Mab to receive $180M upfront, $20M on P-I results, and is eligible to receive ~$1.74B which include $840M as development & regulatory milestones while remaining as commercial milestones along […]readmore
Shots: Morphic will receive a $20M as license fee and is eligible to receive milestones and royalties on sales of any commercialized therapy while AbbVie has exercised a license option […]readmore
Shots: Bio-Thera to receive $165M upfront, regulatory, and commercial milestones and is eligible to receive royalties on sales of the product. BeiGene to get the right to develop, manufacture, and […]readmore
Shots: Abeona to receive $7M including $3M up front, $4M inventory purchase price, including GMP-sourced CLN1 plasmid and is eligible to receive $56M as clinical, regulatory, and commercial milestones along […]readmore
Shots: Sangamo to receive $75M upfront within 30 days, $720M milestone payments including up to $420M in development milestones and up to $300M in commercial milestones plus royalties on sales […]readmore
Shots: Bio-Thera will take care of full development, and commercial supply of BAT2506 out of the manufacturing facilities in Guangzhou, China. Additionally, the agreement will utilize Pharmapark’s local presence, sales, […]readmore
Shots: Dragonfly to receive $55M upfront, additional payments for development, regulatory and sales milestones plus royalties on sales of approved products. BMS to get exclusive option to license exclusive worldwide […]readmore
Shots: Hansa to receive $10M up front, up to $397.5M as development, regulatory & commercial milestones. Hansa will book all sales of therapy and will get royalties on gene therapy […]readmore
Shots: Takeda will screen & optimize compounds derived from Debiopharm’s Debio 1454M program to identify candidates for further development to treat IBD and other GI disorders Takeda will pursue the […]readmore